Results

Ocugen Inc.

10/27/2021 | Press release | Distributed by Public on 10/27/2021 04:40

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)